SAR and in Vivo Evaluation of 4-aryl-2-aminoalkylpyrimidines As Potent and Selective Janus Kinase 2 (JAK2) Inhibitors
Overview
Authors
Affiliations
We report the discovery of a series of 4-aryl-2-aminoalkylpyrimidine derivatives as potent and selective JAK2 inhibitors. High throughput screening of our in-house compound library led to the identification of hit 1, from which optimization resulted in the discovery of highly potent and selective JAK2 inhibitors. Advanced lead 10d demonstrated a significant dose-dependent pharmacodynamic and antitumor effect in a mouse xenograft model. Based upon the desirable profile of 10d (XL019) it was advanced into clinical trials.
CDC7 as a novel biomarker and druggable target in cancer.
Liu R, Huang Y Clin Transl Oncol. 2022; 24(10):1856-1864.
PMID: 35657477 DOI: 10.1007/s12094-022-02853-4.
Babu S, Nagarajan S, Sathish S, Negi V, Sohn H, Madhavan T Front Pharmacol. 2022; 13:837369.
PMID: 35529449 PMC: 9068899. DOI: 10.3389/fphar.2022.837369.
Beinhoff P, Sabharwal L, Udhane V, Maranto C, LaViolette P, Jacobsohn K Cancers (Basel). 2021; 13(20).
PMID: 34680353 PMC: 8533841. DOI: 10.3390/cancers13205204.
Targeted drug combination therapy design based on driver genes.
Zsakai L, Sipos A, Dobos J, Eros D, Szantai-Kis C, Banhegyi P Oncotarget. 2019; 10(51):5255-5266.
PMID: 31523388 PMC: 6731102. DOI: 10.18632/oncotarget.26985.
Kaur M, Singh P, Singh M, Bahadur R, Silakari O Mol Divers. 2017; 22(1):95-112.
PMID: 29138965 DOI: 10.1007/s11030-017-9794-z.